Conleth G. Murphy, MD | Authors

HER2-Positive Breast Cancer: Beyond Trastuzumab

April 30, 2010

This review explores the use of several such agents, including lapatinib (Tykerb), HSP90 inhibitors, T-DM1, and other tyrosine kinase inhibitors. Emerging data from trials of these agents indicate that the HER2 pathway remains a valid therapeutic target following disease progression on trastuzumab.

Move to abandon anthracyclines in adjuvant breast cancer care is premature

November 02, 2008

Anthracyclines have occupied a prominent position in the adjuvant systemic treatment of early breast cancer for decades. Th is position was supported by the evidence from the latest overview of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) showing an absolute survival benefit of about 4% at 10 years for anthracycline-containing regimens versus CMF-like regimens.

Aromatase Inhibitors and Arthralgia: A Growing Pain?

November 01, 2008

In the current issue of ONCOLOGY, Henry et al comprehensively review the current state of knowledge regarding the incidence and pathogenesis of aromatase inhibitor (AI)-associated arthralgia, and its potential implications in terms of delivering adequate, effective adjuvant therapy.